Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Proarrhythmic events.

D P Zipes1

  • 1Krannert Institute of Cardiology, Department of Medicine, Indiana University School of Medicine, Indianapolis 46202.

The American Journal of Cardiology
|January 15, 1988
PubMed
Summary
This summary is machine-generated.

Nearly all antiarrhythmic drugs can cause arrhythmias, especially in patients with ventricular tachycardia. Proarrhythmic events occurred in 8% of patients and 4% of drug trials, necessitating prompt drug discontinuation.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Task Force on Sudden Cardiac Death, European Society of Cardiology. Summary of recommendations].

Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology·2002
Same author

What's bad for the gander...women and sudden cardiac death.

Heart (British Cardiac Society)·2002
Same author

Task Force on Sudden Cardiac Death, European Society of Cardiology.

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology·2002
Same author

President's page: guidelines: tools for building better patient care.

Journal of the American College of Cardiology·2001
Same author

Saving time saves lives.

Circulation·2001
Same author

President's page: quality of care: a moving target worthy of pursuit.

Journal of the American College of Cardiology·2001
Same journal

Real-World Effectiveness and Tolerability of Sacubitril/Valsartan in Octogenarian Patients With Heart Failure: Results From the PARACHUTER Study.

The American journal of cardiology·2026
Same journal

ECG-Guided Conduction Pathways as a Lever to Shorten Post-TAVI Hospitalization.

The American journal of cardiology·2026
Same journal

Cystatin-C versus creatinine and kidney function in heart failure with preserved ejection fraction: a SOGALDI-PEF analysis.

The American journal of cardiology·2026
Same journal

Balloon-expandable versus Self-expanding Valves in Patients with Small Aortic Annuli Undergoing Transcatheter Aortic Valve Replacement.

The American journal of cardiology·2026
Same journal

Drug-Coated Balloons versus Drug-Eluting Stents following Coronary Atherectomy in Severely Calcified Lesions: A Systematic Review and Meta-Analysis.

The American journal of cardiology·2026
Same journal

Prehospital Statin Therapy and Outcomes in ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.

The American journal of cardiology·2026
See all related articles

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Medicine

Background:

  • Antiarrhythmic agents, while crucial for treating cardiac arrhythmias, possess an inherent risk of inducing proarrhythmic events.
  • Factors influencing antiarrhythmic drug efficacy and safety include drug interactions, altered pharmacokinetics, idiosyncratic reactions, electrolyte imbalances, and autonomic nervous system modulation.

Purpose of the Study:

  • To evaluate the incidence and characteristics of proarrhythmic events associated with antiarrhythmic drug therapy.
  • To highlight the importance of standardized reporting and management guidelines for proarrhythmic events.

Main Methods:

  • Analysis of 1,080 drug trials in 412 patients treated for ventricular tachycardia or ventricular fibrillation.
  • Systematic review of reported proarrhythmic events and their clinical context.

Related Experiment Videos

Main Results:

  • Proarrhythmic events occurred in 33 patients (8%) and 43 drug trials (4%).
  • Proarrhythmic events were more frequent during treatment for sustained ventricular tachycardia compared to ventricular fibrillation or nonsustained ventricular tachycardia.

Conclusions:

  • Discontinuation of the offending antiarrhythmic agent is the primary management strategy for proarrhythmic events.
  • Further therapeutic recommendations depend on the specific arrhythmia and clinical presentation, emphasizing individualized patient care.